

This listing of claims will replace all prior versions, and listings, of claims in our amendments or responses to Office actions.

Listing of Claims:

Claims 1-20 (cancelled)

31 (new). An isolated or purified antibody or binding fragment of an antibody, which specifically binds to a cytokine complex comprising a mature polypeptide of SEQ ID NO: 2 or 4 and a mature polypeptide of SEQ ID NO: 12 or 13.

32 (new). The antibody or binding fragment of claim 31, wherein the antibody or binding fragment thereof does not bind to SEQ ID NO: 2, 4, 12, or 13 individually.

33 (new). The antibody or binding fragment of claim 31, wherein the cytokine complex comprises a mature polypeptide of SEQ ID NO: 2 and a mature polypeptide of SEQ ID NO: 12.

34 (new). The antibody or binding fragment of claim 33 which is an agonist antibody or binding fragment.

35 (new). The antibody or binding fragment of claim 34, wherein the agonist antibody or binding fragment enhances the binding of the cytokine complex to a receptor complex comprising CNTFR, LIFR, and gp130.

36 (new). The antibody or binding fragment of claim 35, wherein the receptor complex comprises human CNTFR, human LIFR, and human gp130.

37 (new). The antibody or binding fragment of claim 31, which is an antagonist antibody or binding fragment.

38 (new). The antibody or binding fragment of claim 37, wherein the antagonist antibody inhibits binding of the cytokine complex to a receptor complex comprising CNTFR, LIFR, and gp130.

39 (new). The antibody or binding fragment of claim 38, wherein the receptor complex comprises human CNTFR, human LIFR, and human gp130.

40 (new). The antibody or binding fragment of claim 31, wherein the binding fragment is selected from the group consisting of: a Fab fragment, a Fab2 fragment, a single chain antibody, and an Fv fragment.

41 (new). The antibody or binding fragment of claim 31, wherein the antibody is a polyclonal antibody.

42 (new). The antibody or binding fragment of claim 31, wherein the antibody is a monoclonal antibody.

43. The antibody or binding fragment of claim 31, wherein the antibody is a recombinant antibody.

44 (new). The antibody or binding fragment of claim 31, wherein the antibody is selected from the group consisting of: a humanized antibody, a chimeric antibody, a fully human antibody.

45 (new). The antibody or binding fragment of claim 31, which is detectably labeled.

46 (new). A composition comprising the antibody or binding fragment of claim 31 and an aqueous carrier.

47 (new). The composition of claim 46, wherein the aqueous carrier is selected from the group consisting of: water, saline, and a buffer.

48 (new). The composition of claim 46, wherein the aqueous carrier is a pharmaceutically acceptable aqueous carrier.

49 (new). A kit comprising the antibody or binding fragment of claim 31, a compartment containing the antibody or binding fragment, and instructions for use or disposal of reagents in the kit.